Abstract
The prevalence of diabetes mellitus is growing rapidly. According to the global report of International Diabetes Fedration (IDF), about 382 million people are suffering from diabetes and among them, 90% cases were of type-II. By 2035, it is expected that this number will reach to 592 million. In the last 5 decades, various efforts have been put towards the development of synthetic medicines or synergistic combination of herbal and synthetic medicines to treat diabetes mellitus. Polypeptide-k is an antihyperglycaemic protein isolated from dried seeds collected from ripened fruits of Momordica charantia. Extensive research has been carried out in the last fifteen years on polypeptide-k to explore its potential applications for the treatment of both types of diabetes mellitus. This review highlights the available marketed formulations and research investigations conducted on humans to prove the potential of polypeptide-k as an antihyperglycaemic agent. This article also marks the reasons and need for oral delivery of polypeptide-k.
Keywords: Antihyperglycaemic protein, Diabetes mellitus, Marketed formulations, Momordica charantia, Oral delivery, Polypeptide-k.
Current Drug Delivery
Title:Oral Delivery of Antidiabetic Polypeptide-k: Journey so far and the Road Ahead
Volume: 13 Issue: 2
Author(s): Puneet Kaur, Varun Garg, Monica Gulati and Sachin Kumar Singh
Affiliation:
Keywords: Antihyperglycaemic protein, Diabetes mellitus, Marketed formulations, Momordica charantia, Oral delivery, Polypeptide-k.
Abstract: The prevalence of diabetes mellitus is growing rapidly. According to the global report of International Diabetes Fedration (IDF), about 382 million people are suffering from diabetes and among them, 90% cases were of type-II. By 2035, it is expected that this number will reach to 592 million. In the last 5 decades, various efforts have been put towards the development of synthetic medicines or synergistic combination of herbal and synthetic medicines to treat diabetes mellitus. Polypeptide-k is an antihyperglycaemic protein isolated from dried seeds collected from ripened fruits of Momordica charantia. Extensive research has been carried out in the last fifteen years on polypeptide-k to explore its potential applications for the treatment of both types of diabetes mellitus. This review highlights the available marketed formulations and research investigations conducted on humans to prove the potential of polypeptide-k as an antihyperglycaemic agent. This article also marks the reasons and need for oral delivery of polypeptide-k.
Export Options
About this article
Cite this article as:
Kaur Puneet, Garg Varun, Gulati Monica and Kumar Singh Sachin, Oral Delivery of Antidiabetic Polypeptide-k: Journey so far and the Road Ahead, Current Drug Delivery 2016; 13 (2) . https://dx.doi.org/10.2174/1567201812666151012113221
DOI https://dx.doi.org/10.2174/1567201812666151012113221 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current and Emerging Treatments for Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis
Reviews on Recent Clinical Trials Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry A Sweeping Role for MicroRNAs in Neuronal Disease, Vascular Disorders, and as Prognostic Indicators
Current Neurovascular Research MicroRNAs in Diabetic β Cell Dysfunction and their Role as Biomarkers
Current Signal Transduction Therapy Medical Complications of Binge Eating Disorder
Current Women`s Health Reviews Hypertension in Polycystic Ovary Syndrome: Novel Insights
Current Hypertension Reviews Light-at-Night-Induced Circadian Disruption, Cancer and Aging
Current Aging Science Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Epigenetic Modifications Associated with the Pathogenesis of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets On Epistasis: A Methodological Review for Detecting Gene-Gene Interactions Underlying Various Types of Phenotypic Traits
Recent Patents on Biotechnology The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Design and Synthesis of Novel 5-Arylisoxazole-1,3,4-thiadiazole Hybrids as α-Glucosidase Inhibitors
Letters in Drug Design & Discovery Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy Contribution of Large Animals to Translational Research on Prenatal Programming of Obesity and Associated Diseases
Current Pharmaceutical Biotechnology An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?
Current Pharmaceutical Design Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy
Current Pharmaceutical Design Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia
Current Drug Targets Resident and Non-Resident Stem Cells in Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets